Ovarian Cancer News
Continued Chemotherapy in Advanced Ovarian Cancer (August 9, 2010)Continuing chemotherapy following initial treatment of advanced ovarian cancer may improve survival, according to a study published in Cancer. Ovarian cancer has the highest mortality rate of all gynecologic cancers. It is the fifth leading cause of cancer... Continue Reading
Olaparib Active Against Advanced Ovarian Cancer and Breast Cancer with BRCA Mutations (July 20, 2010)Previously treated advanced breast and ovarian cancer patients with BRCA1 or BRCA2 gene mutation may benefit from treatment with the oral investigational drug olaparib. These findings were recently published in the journal The Lancet.[1],[2] Although... Continue Reading
High Circulating Vitamin D Levels Don’t Reduce Risk of Less Common Cancers (July 13, 2010)High levels of vitamin D in the bloodstream do not appear to reduce the risk of seven less common cancers: endometrial, esophageal, stomach, ovarian, pancreatic, kidney, and non-Hodgkin’s lymphoma. In fact, there was a suggestion that people with the... Continue Reading
Combination of Trabectedin and Pegylated Liposomal Doxorubicin Modestly Delays Progression of Recurrent Ovarian Cancer (July 9, 2010)The combination of the investigational agent trabectedin with pegylated liposomal doxorubicin (PLD) resulted in a 1.5-month improvement in progression-free survival in women with recurrent ovarian cancer. Final information about overall survival is not... Continue Reading
Olaparib Shows Promise in High-grade Serous Ovarian Cancer (June 16, 2010)Advanced serous ovarian cancer responds to single-agent treatment with olaparib, according to the results of a Phase II study presented at the 2010 annual meeting of the American Society of Clinical Oncology.[1] Ovarian cancer has the highest mortality... Continue Reading
Avastin Delays Progression of Advanced Ovarian Cancer (June 8, 2010)In a Phase III clinical trial, the addition of the targeted therapy Avastin® (bevacizumab) to chemotherapy, followed by maintenance therapy with Avastin, slowed cancer progression among women with advanced ovarian, primary peritoneal, or Fallopian tube... Continue Reading
Promising Results for Ovarian Cancer Screening Strategy (June 3, 2010)In a study of postmenopausal women at average-risk of ovarian cancer, promising results were obtained with an ovarian cancer screening strategy that combined information about trends in CA-125 blood test results and age, followed as needed by transvaginal... Continue Reading
Chemotherapy Drug Patupilone Fails in Advanced Ovarian Cancer (June 2, 2010)The chemotherapy drug patupilone (EPO906) has failed to show a survival advantage over Doxil®/Caelyx® (pegylated liposomal doxorubicin) in patients with advanced ovarian cancer that is resistant to platinum-based therapy. Novartis reported the results... Continue Reading
Olaparib Active Against Advanced Ovarian Cancer in Women with BRCA Mutations (May 5, 2010)Olaparib, an investigational targeted therapy, resulted in a 61.5% response rate among women with platinum-sensitive, advanced ovarian cancer and a BRCA gene mutation. These results were recently published in the Journal of Clinical Oncology.[1] Although... Continue Reading
One Step Closer to Early Detection of Ovarian Cancer (April 13, 2010)A four-biomarker screening assay detected 86% of early-stage ovarian cancers with a 98% specificity level; this leads researchers to conclude that the assay could eventually become the first-line test in a two-step strategy for early detection of the... Continue Reading
Latest Ovarian Cancer News By Stage
Recurrent Ovarian Cancer
Olaparib Active Against Advanced Ovarian Cancer and Breast Cancer with BRCA Mutations (July 20, 2010)
Previously treated advanced breast and ovarian cancer patients with BRCA1 or BRCA2 gene mutation may benefit from treatment with the oral investigational drug olaparib. These findings were recently published in the journal The Lancet.[1],[2] Although... Continue Reading
Combination of Trabectedin and Pegylated Liposomal Doxorubicin Modestly Delays Progression of Recurrent Ovarian Cancer (July 9, 2010)The combination of the investigational agent trabectedin with pegylated liposomal doxorubicin (PLD) resulted in a 1.5-month improvement in progression-free survival in women with recurrent ovarian cancer. Final information about overall survival is not... Continue Reading
Olaparib Active Against Advanced Ovarian Cancer in Women with BRCA Mutations (May 5, 2010)Olaparib, an investigational targeted therapy, resulted in a 61.5% response rate among women with platinum-sensitive, advanced ovarian cancer and a BRCA gene mutation. These results were recently published in the Journal of Clinical Oncology.[1] Although... Continue Reading
Farletuzumab Shows Promise in Relapsed Ovarian Cancer (October 7, 2009)According to the results of a Phase II clinical trial, the investigational drug farletuzumab may have anticancer activity in the treatment of relapsed ovarian cancer when combined with chemotherapy. These results were presented at a European cancer conference. Many... Continue Reading
September Is National Ovarian Cancer Awareness Month (September 1, 2009)As the month of September brings ovarian cancer into focus, it’s time to increase public understanding about the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated ovarian cancer... Continue Reading
More Recurrent Ovarian CancerScreening/Prevention Ovarian Cancer
High Circulating Vitamin D Levels Don’t Reduce Risk of Less Common Cancers (July 13, 2010)
High levels of vitamin D in the bloodstream do not appear to reduce the risk of seven less common cancers: endometrial, esophageal, stomach, ovarian, pancreatic, kidney, and non-Hodgkin’s lymphoma. In fact, there was a suggestion that people with the... Continue Reading
Promising Results for Ovarian Cancer Screening Strategy (June 3, 2010)In a study of postmenopausal women at average-risk of ovarian cancer, promising results were obtained with an ovarian cancer screening strategy that combined information about trends in CA-125 blood test results and age, followed as needed by transvaginal... Continue Reading
One Step Closer to Early Detection of Ovarian Cancer (April 13, 2010)A four-biomarker screening assay detected 86% of early-stage ovarian cancers with a 98% specificity level; this leads researchers to conclude that the assay could eventually become the first-line test in a two-step strategy for early detection of the... Continue Reading
Test Available for Pre-surgical Evaluation of Ovarian Mass (March 11, 2010)For women who require surgery for an ovarian mass, the OVA1™ test may help identify the most appropriate type of surgeon. The test assesses the likelihood that cancer is present; when cancer is likely, surgery may best be performed by a gynecologic... Continue Reading
Regular Aspirin Use May Reduce Risk of Ovarian Cancer (February 17, 2010)According to results from the Iowa Women’s Health Study, regular aspirin use may reduce the risk of developing ovarian cancer but does not appear to affect the risk of endometrial cancer. These results were published in Cancer Epidemiology, Biomarkers,... Continue Reading
More Screening/Prevention Ovarian CancerStage I Ovarian Cancer
September Is National Ovarian Cancer Awareness Month (September 1, 2009)
As the month of September brings ovarian cancer into focus, it’s time to increase public understanding about the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated ovarian cancer... Continue Reading
Fertility Preservation Appears to Be Safe for Young Women with Early-stage Ovarian Cancer (August 11, 2009)Preservation of the non-cancerous ovary and the uterus appears to be safe for young women with Stage IA or IC ovarian cancer and allows women to preserve their fertility. These results were published in Cancer. Women who confront a cancer diagnosis at... Continue Reading
Ovarian Cancer National Alliance Announces Eleventh Annual Conference (March 8, 2009)Ovarian Cancer National Alliance Announces Eleventh Annual Conference This year the Ovarian Cancer National Alliance will hold their eleventh annual conference, titled “Creating Currents of Change,” on Tuesday, July 8 through Thursday, July... Continue Reading
Specialty Hospitals Associated with Improved Survival in Early Ovarian Cancer (March 8, 2009)Specialty Hospitals Associated with Improved Survival in Early Ovarian Cancer Hospitals that specialize in care for ovarian cancer are associated with significantly improved survival for women with early ovarian cancer. These results were recently reported... Continue Reading
Further Evidence in Favor of Care for Ovarian Cancer Patients by Gynecologic Oncologists (March 8, 2009)Further Evidence in Favor of Care for Ovarian Cancer Patients by Gynecologic Oncologists According to an article recently published in Gynecologic Oncology, patients under 55 years of age with Stages IC–II ovarian cancer were more likely to receive... Continue Reading
More Stage I Ovarian CancerStage II-IV Ovarian Cancer
Continued Chemotherapy in Advanced Ovarian Cancer (August 9, 2010)
Continuing chemotherapy following initial treatment of advanced ovarian cancer may improve survival, according to a study published in Cancer. Ovarian cancer has the highest mortality rate of all gynecologic cancers. It is the fifth leading cause of cancer... Continue Reading
Olaparib Shows Promise in High-grade Serous Ovarian Cancer (June 16, 2010)Advanced serous ovarian cancer responds to single-agent treatment with olaparib, according to the results of a Phase II study presented at the 2010 annual meeting of the American Society of Clinical Oncology.[1] Ovarian cancer has the highest mortality... Continue Reading
Avastin Delays Progression of Advanced Ovarian Cancer (June 8, 2010)In a Phase III clinical trial, the addition of the targeted therapy Avastin® (bevacizumab) to chemotherapy, followed by maintenance therapy with Avastin, slowed cancer progression among women with advanced ovarian, primary peritoneal, or Fallopian tube... Continue Reading
Chemotherapy Drug Patupilone Fails in Advanced Ovarian Cancer (June 2, 2010)The chemotherapy drug patupilone (EPO906) has failed to show a survival advantage over Doxil®/Caelyx® (pegylated liposomal doxorubicin) in patients with advanced ovarian cancer that is resistant to platinum-based therapy. Novartis reported the results... Continue Reading
Olaparib Active Against Advanced Ovarian Cancer in Women with BRCA Mutations (May 5, 2010)Olaparib, an investigational targeted therapy, resulted in a 61.5% response rate among women with platinum-sensitive, advanced ovarian cancer and a BRCA gene mutation. These results were recently published in the Journal of Clinical Oncology.[1] Although... Continue Reading
More Stage II-IV Ovarian Cancer